Renin-dependent water intake in hypovolemia. 1988

J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
Department of Medicine, University of Heidelberg, Federal Republic of Germany.

The role of the renin-angiotensin system as a mediator of water intake, induced by hypovolemia after polyethylene glycol (PEG) injection, was investigated. Blockade of angiotensin I converting enzyme and of angiotensin receptors was used as a pharmacological tool. A significant reduction of water intake was observed when angiotensin I converting enzyme was inhibited by captopril and enalapril. In PEG-treated rats with blockade of angiotensin I converting enzyme, hypertonic saline injection continued to elicit substantial drinking. Normalization of low blood pressure by vasopressin infusions in PEG and captopril treated rats did not interfere with the antidipsogenic effectiveness of converting enzyme blockade. The angiotensin II receptor antagonist, saralasin, also reduced PEG-induced drinking although less effectively than converting enzyme inhibitors. We conclude that water intake due to isotonic depletion of the extracellular fluid compartment may depend on the activity of the renin-angiotensin system.

UI MeSH Term Description Entries
D008297 Male Males
D009995 Osmosis Tendency of fluids (e.g., water) to move from the less concentrated to the more concentrated side of a semipermeable membrane. Osmoses
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001810 Blood Volume Volume of circulating BLOOD. It is the sum of the PLASMA VOLUME and ERYTHROCYTE VOLUME. Blood Volumes,Volume, Blood,Volumes, Blood
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012504 Saralasin An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. 1-Sar-8-Ala Angiotensin II,1-Sarcosine-8-Alanine Angiotensin II,(Sar(1),Ala(8))ANGII,(Sar1,Val5,Ala8)Angiotensin II,Angiotensin II, Sar(1)-Ala(8)-,Angiotensin II, Sarcosyl(1)-Alanine(8)-,Sar-Arg-Val-Tyr-Val-His-Pro-Ala,Saralasin Acetate,Saralasin Acetate, Anhydrous,Saralasin Acetate, Hydrated,1 Sar 8 Ala Angiotensin II,1 Sarcosine 8 Alanine Angiotensin II,Angiotensin II, 1-Sar-8-Ala,Angiotensin II, 1-Sarcosine-8-Alanine,Anhydrous Saralasin Acetate,Hydrated Saralasin Acetate

Related Publications

J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
July 1979, The American journal of physiology,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
April 1983, Experientia,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
January 1979, Eksperimentalna meditsina i morfologiia,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
January 1986, Acta physiologica et pharmacologica Bulgarica,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
March 2003, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
July 1972, Medicina,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
January 2010, The journal of physiological sciences : JPS,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
March 1976, Pharmacology, biochemistry, and behavior,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
September 1979, Physiology & behavior,
J F Mann, and S Eisele, and R Rettig, and T Unger, and A K Johnson, and D Ganten, and E Ritz
January 1975, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!